Cancer treatment.Insert Therapeutics Inc., a majority-owned subsidiary majority-owned subsidiary A firm in which more than 50% of outstanding voting stock is owned by the parent company. of Pasadena-based Arrowhead arrowhead, any plant of the genus Sagittaria, widely distributed marsh or aquatic herbs of the primitive family Alismataceae (water-plantain family). The name derives from the arrowhead-shaped leaves of many species. Research Corp. said last week that it has applied to the U.S. Food and Drug Administration for clearance to launch a Phase 1 clinical trial phase 1 clinical trial Phase 1 study. See Phase study. for its lead cancer-fighting compound, IT- 101. IT-101 combines Insert's patented delivery system, Cyclosert, with an existing anti-cancer compound called camptothecin to treat patients with certain types of solid tumors. Camptothecin is an alkaloid developed in the 1960s that was shown in the laboratory to be effective against a broad spectrum of cancers. It was never brought to market because it doesn't dissolve easily or metabolize me·tab·o·lize v. 1. To subject to metabolism. 2. To produce by metabolism. 3. To undergo change by metabolism. metabolize to subject to or be transformed by metabolism. well in humans. Insert believes its nanotechnology-based delivery system, which involves tiny molecules of glucose called cyclodextrins, can overcome those challenges. The technology is licensed from the California Institute of Technology California Institute of Technology, at Pasadena, Calif.; originally for men, became coeducational in 1970; founded 1891 as Throop Polytechnic Institute; called Throop College of Technology, 1913–20. and was developed by chemical engineering professor and Insert founder Mark Davis. Phase 1 trials evaluate safety, tolerability and how an experimental drug metabolizes in humans. The IT-101 study is planned to be held at the City of Hope Cancer Center in Duarte. |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion